Skip to main navigation Skip to search Skip to main content

Subset of patients with verrucous carcinoma of the oral cavity benefit from treatment with methotrexate

  • K.H. Karagozoglu
  • , J. Buter
  • , C.R. Leemans
  • , D.H.F. Rietveld
  • , S. van den Vijfeijken
  • , I. van der Waal

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Oral verrucous carcinoma (OVC) is a low-grade variant of squamous cell carcinoma (SCC) with a distinctive morphology and specific pattern of behaviour that is often diagnosed in elderly patients. Resection is the treatment of choice, with radiotherapy as a reasonable alternative. In this retrospective case review we present our experience and outcomes in a group of 12 patients with various stages of OVC who had not been treated conventionally because of the extent of their lesions and their poor general condition. All patients were given chemotherapy with methotrexate, which was given by various routes and in different doses during the period 1972-2010. In 11 patients treatment with methotrexate alone was beneficial. One patient failed to respond. Methotrexate used alone as chemotherapy may minimise morbidity and improve quality of life, particularly among elderly patients.
Original languageEnglish
Pages (from-to)513-518
JournalBritish Journal of Oral & Maxillofacial Surgery
Volume50
Issue number6
DOIs
Publication statusPublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Subset of patients with verrucous carcinoma of the oral cavity benefit from treatment with methotrexate'. Together they form a unique fingerprint.

Cite this